Cypher Impresses FDA Panel; Approval Recommended With More Drug Data

The pharmacokinetic study specified by FDA's Circulatory System Devices Panel as a condition of approval for Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent could become a standard requirement for future drug/device combination trials